CD34+ CML cells have been shown to express Fas-receptor (FAS-R) or CD95, and interferon-α (IFN-α) therapy has been found to further upregulate FAS-R expression. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.